News Home

Is Allogene Therapeutics Inc (ALLO) a Stock to Watch After Gaining 8.39% This Week?

Tuesday, February 27, 2024 11:54 AM | InvestorsObserver Analysts

Mentioned in this article

Is Allogene Therapeutics Inc (ALLO) a Stock to Watch After Gaining 8.39% This Week?

The market has been high on Allogene Therapeutics Inc (ALLO) stock recently. ALLO gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Allogene Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALLO!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ALLO Stock Today?

Allogene Therapeutics Inc (ALLO) stock is up 8.86% while the S&P 500 is down -0.06% as of 11:42 AM on Tuesday, Feb 27. ALLO is up $0.41 from the previous closing price of $4.63 on volume of 736,301 shares. Over the past year the S&P 500 is up 27.22% while ALLO is down -20.38%. ALLO lost -$2.24 per share in the over the last 12 months. To screen for more stocks like Allogene Therapeutics Inc click here.

More About Allogene Therapeutics Inc

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. Click Here to get the full Stock Report for Allogene Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App